UNSPSC 51284602: Doripenem

This classification denotes a beta-lactam antibiotic with the molecular formula C15H24N4O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BHV525JOBH, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but generally known as doripenem, which bears US NIH Compound Identifier 73303.

UNSPSC 51284602 Doripenem is a Commodity code nominally classifying a specific antibiotic pharmaceutical, but recent state and local procurement activity under this code shows substantial mismatch with the product itself. State and local governments are soliciting pharmaceuticals and medical supplies broadly—naloxone and drug deactivation systems, generic multi-source drugs, first-aid medical consumables, and direct-to-manufacturer prescription programs—rather than doripenem specifically. The code appears to serve as a catch-all for pharmaceutical procurement across health departments, emergency services, and cooperative purchasing alliances, with issuing bodies ranging from county health departments and municipal fire services to state health commissions and multistate cooperative purchasing organizations.

Recent activity spans Florida, Texas, Minnesota, and Oregon through a mix of issuing bodies. Seminole County, Florida (IFB 60459723LAS, July 2026) sought 1,900 units of naloxone and 800 drug deactivation systems annually for its community health program with quarterly deliveries; the City of Tampa (IFB 26-P-00145, March 2026) issued a $700,000 sheltered-market bid for 169 line items of medical and first-aid supplies for its Fire Department Rescue Division, restricted to certified Small Local Business Enterprises with a 5 percent bid discount; the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) solicited generic multi-source pharmaceuticals and OTC products for state and local facilities across multiple states, with awards effective July 1, 2026; and the Texas Health and Human Services Commission (RFI HHS0017013, April 2026) issued an exploratory request for information on direct-to-manufacturer prescription program capability. The code shows steady activity but little apparent procurement for doripenem as a specific product, suggesting that vendors should verify code alignment with actual pharmaceutical or medical-supply requirements in each opportunity rather than assume the code name drives the scope.